| Website | sagerx.com |
| Category | BioTech |
| Employees |
| TOTAL | $35M |
| VENTURE FUNDING TOTAL | $35M |
| Series A, 10/11 Third Rock Ventures | $35M |
SAGE Therapeutics is dedicated to the health and wellbeing of patients with central nervous system (CNS) disorders. Our mission is to discover, develop and deliver novel medicines for many of today’s most debilitating and disabling CNS disorders by leveraging compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers.
